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3Abstract
Purpose:
Mutations in POLG, the most common single gene cause of inherited mitochondrial disease
are diagnostically challenging owing to clinical heterogeneity and overlap between
syndromes. We aimed to improve the clinical recognition of POLG-related disorders in the
pediatric population.
Methods:
We performed a multinational, phenotype: genotype study using patients from three centers,
two Norwegian and one from the UK. Patients with age of onset <12 years and confirmed
pathogenic biallelic POLG mutations were considered eligible.
Results:
A total of 27 patients were identified with a median age at onset of 11 months (range 0.6 -
80.4). The majority presented with global developmental delay (n=24/24, 100%), hypotonia
(n=22/23, 96 %) and faltering growth (n=24/27, 89%). Epilepsy was common, but notably
absent in patients with the myocerebrohepatopathy spectrum phenotype. We identified two
novel POLG gene mutations.
Conclusion:
Our data suggest that POLG-related disease should be suspected in any child presenting with
diffuse neurological symptoms. Full POLG sequencing is recommended since targeted
screening may miss mutations. Finally, we simplify the classification of POLG related disease
in children using epilepsy as the crucial defining element; we show that Alpers and MCHS
follow different outcomes and that they manifest different degrees of respiratory chain
dysfunction.
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5INTRODUCTION
POLG (OMIM *174763) encodes the catalytic subunit of DNA polymerase gamma, the
enzyme responsible for mtDNA replication and repair.1 Mutations in POLG result in mtDNA
depletion and/or multiple deletions and are considered the most common cause of inherited
mitochondrial disorders.2,3
The first pathogenic POLG mutation was identified in families with autosomal dominant
progressive external ophthalmoplegia (ADPEO).4 Subsequently, POLG mutations have been
associated with a wide range of overlapping clinical phenotypes including: (a) Alpers
syndrome, (b) myocerebrohepatopathy spectrum (MCHS), (c) myoclonic epilepsy, myopathy,
sensory ataxia (MEMSA) - includes disorders previously described as spinocerebellar ataxia
with epilepsy (SCAE), (d) ataxia neuropathy spectrum (ANS) including phenotypes
previously described as sensory ataxia, neuropathy, dysarthria and ophthalmoplegia
(SANDO) and mitochondrial recessive ataxia syndrome (MIRAS), (e) ADPEO, and (f)
autosomal recessive PEO.5,6 Rare phenotypes include mitochondrial neurogastrointestinal
encephalopathy (MNGIE)-like phenotype,7 mitochondrial encephalomyopathy, lactic acidosis
and stroke-like episodes (MELAS)-like phenotype,8 premature ovarian failure,9 parkinsonism,
psychiatric disorders, cataract,10 sensorineural hearing loss, diabetes and cardiomyopathy.11
Alpers syndrome and MCHS are the two phenotypes most commonly reported with POLG
mutations in the pediatric population.12 The neuropathology of Alpers syndrome (OMIM #
203700) was first described in 1931,13 but it was not until the 1980s that the link to
mitochondrial dysfunction was made.14 Pathogenic POLG mutations causing Alpers
syndrome were first reported in 2004.15 This syndrome is almost universally fatal in
childhood, making it one of the most severe forms in the spectrum of POLG-related disease.
6Alpers syndrome is characterized by progressive encephalopathy with psychomotor
regression, refractory epilepsy and characteristic liver disease,16 presenting most frequently
during infancy after an initial period of normal development.5,6 The most common early
seizure types are focal and focal evolving to bilateral convulsive seizures, with predominance
of epileptiform discharges over occipital regions.17 The seizure semiology may evolve with
time to more complex forms including epilepsia partialis continua, myoclonic epilepsy and
status epilepticus.17-19
Hepatic involvement may progress rapidly to end-stage liver failure, and may be triggered by
valproic acid,20,21 but is not universal; affected children with biallelic POLG mutations with
encephalopathy without liver failure are well recognised.11,19 Diagnostic criteria for Alpers
syndrome include characteristic liver histopathological changes, namely two of:
microvesicular steatosis, bile ductular proliferation, hepatocyte dropout, bridging fibrosis or
cirrhosis, collapse of liver cell plates, parenchymal lobular architecture, regenerative nodules
and oncocytic changes in scattered hepatocytes not affected by steatosis.12
MCHS is also severe and fatal, but less frequently reported than Alpers syndrome. MCHS
most frequently presents between the neonatal period and three years and is characterized by a
triad of myopathy or hypotonia, developmental delay or encephalopathy and liver
dysfunction.12 Diagnostic criteria for MCHS include: absence of hepatic histopathological
features of classical Alpers and at least two of the following: neuropathy, seizures, elevated
blood or cerebrospinal fluid (CSF) lactate, dicarboxylic aciduria, renal tubular dysfunction
with aminoaciduria, glycosuria or bicarbonaturia, hearing loss, abnormal MRI, with either
cerebral volume loss, delayed myelination or white matter disease, and either isolated
7deficiency of complex IV (cytochrome c oxidase) or a combined defect of two or more
oxidative phosphorylation complexes in skeletal muscle or liver biopsy.5,6,19,22,23
MNGIE is a rare autosomal recessive mitochondrial disorder usually caused by mutations in
TYMP encoding thymidine phosphorylase, an enzyme involved in nucleoside salvage.
MNGIE usually presents between the first and third decades with severe gastrointestinal
dysmotility, failure to thrive, vomiting, abdominal pain, cachexia and neurological symptoms
including encephalopathy, ptosis, ophthalmoplegia, peripheral neuropathy and muscle
weakness.24,25 POLG mutations have been previously reported in four patients (aged 15- 50
years) with a MNGIE-like phenotype.7,26
In this study we aimed to improve clinical recognition of the extremely heterogeneous and
overlapping pediatric POLG phenotypes by carefully documenting and analysing the natural
history of early onset POLG-related disorders in a large multi-national pediatric cohort.
PATIENTS AND METHODS
Study design and population:
We conducted a multi-center, retrospective study including collaborating centers from
Norway (Haukeland University Hospital, Bergen and University Hospital North of Norway,
Tromsø) and the United Kingdom (Great Ormond Street Hospital, London). All subjects with
age of onset <12 years and biallelic pathogenic POLG variants were considered eligible.
Patients who died before the POLG gene was identified were included if subsequent analysis
of stored samples revealed two pathogenic POLG mutations. Deceased patients were included
if an affected sibling had genetically confirmed POLG-related disease and a similar clinical
course. This study includes detailed clinical data of 13 patients (cases 1, 2, 3, 4, 9, 15,
816,17,18,19, 20, 22 and 24, supplementary file 1) whose POLG mutations had been reported
previously.27,28 Data collection was completed in July 2016.
Patients were phenotypically classified into three groups; Alpers spectrum, MCHS and
MNGIE phenotypes, based on previously described criteria.12,23-25 In view of the rarity of
MCHS, and to provide a better understanding of this particular phenotype, a systematic
literature review (using search terms “POLG”, “mitochondria”, “Alpers”, “infantile
hepatocerebral syndromes”, “mtDNA depletion”, “myocerebrohepatopathy syndrome” in
PubMed, June 2016) was used to identify previously published cases. Cases with age of onset
less than 12 years fulfilling the criteria for MCHS and confirmed bialleleic POLG mutations
were included. These additional MCHS cases were not included in the natural history
analysis.
Data collection:
Patient data (demographic information, clinical features, biochemical data, muscle biopsy,
neurophysiological, neuroimaging and genetic findings, and medical treatment including
response to anti-epileptic drugs) were collected using a structured electronic case report form
which was developed and tested by a pilot study of 10 patients conducted in Haukeland
University Hospital, Bergen, Norway.
Preterm birth was defined as birth before a gestational age of 37 completed weeks.
Microcephaly was defined as head circumference more than two standard deviations below
the mean for age and sex. Renal tubulopathy was defined by the presence of at least three of
the following: tubular acidosis with generalised aminoaciduria, tubular proteinuria,
glycosuria, Fanconi syndrome, or increase in urinary N-acetyl-beta-D-glucosaminidase
9(NAG)/creatinine ratio. Liver involvement was defined by the presence of two or more of the
following in at least two different time points; elevated aspartate aminotransferase (ASAT),
gamma-glutamyltransferase (GGT), bilirubin or ammonia, low serum albumin, or
pathological histological findings on liver biopsy. Hearing impairment was defined as
abnormal auditory evoked response test. Neuroimaging was reviewed by two independent
investigators. Therapy resistant epilepsy was defined using the International League Against
Epilepsy (ILAE) definition.29
Statistical analysis:
Descriptive data analysis was performed using statistic software package SPSS version 23.0.
End of follow-up was defined as the patient’s last visit to the hospital or death. Univariate
survival analysis was performed using log-rank test to compare differences in survival time
between categories.
All genetic studies were performed with informed consent. Ethical approval for the study was
obtained from the Regional Committee for Medical and Health Research Ethics, Western
Norway (REK 2014/1783-4). The study was registered as an audit at Great Ormond Street
Hospital, London, UK.
RESULTS
Demography:
Twenty-seven patients, (15 male, 12 female) from 22 pedigrees (including two patients from
consanguineous families) with genetically confirmed POLG mutations were identified.
Nineteen were diagnosed in the UK and eight in Norway. The majority of patients were
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Northern European (n=23), with two patients from Cyprus, one from United Arab Emirates
and one of Pakistani background (supplementary file 1).
Major clinical features:
Median age at onset of symptoms requiring medical evaluation for the group as a whole was
11.2 months (range 0.6 to 80.4). The majority of cases were born at term with uneventful
pregnancy and delivery (n=26); three cases were small for gestational age and one had
microcephaly. Neonatal problems occurred in 11/27 (41%) of cases, including feeding
difficulties (n=9/25, 36%), vomiting (n=7/21, 33%), hypotonia (n=4/23, 17%), and
hypoglycaemia (n=2/20, 10%). None had neonatal seizures. Disease onset was apparently
spontaneous in 15/26 (58%) and followed an infectious illness in 11 cases (42%).
The predominant clinical features (Table 1) were faltering growth (n=24/27, 89%), global
developmental delay (n=24/24, 100%), hypotonia (n=22/23, 96%), seizures (n=19/26, 73%),
and vomiting (n=22/26, 85%). Focal evolving to bilateral convulsive seizures (Table 1) were
the most common seizure type (n=14/19, 74%). Infantile spasms were observed in one case
(patient 23). Electroencephalogram (EEG) was pathological in 19 of 22 patients (Table 1)
with epileptiform activities predominantly over occipital regions (Fig 1).
Renal tubular dysfunction was observed in three cases, and one child had hypothyroidism.
Ophthalmological involvement occurred in 12 patients, including optic atrophy in two cases
(patients 13 and 16) and cataract in another two cases (patients 19 and 20). Two children
(patients 1 and 21) had hearing impairment.
Biochemical, neurophysiological and muscle biopsy findings:
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Laboratory investigations at presentation revealed increased lactate in blood in 60%
(n=12/20) and in CSF in 40% (n=2/5). Hepatic aminotransferases were increased in 13/20
cases (Table 1). Electromyogram and nerve conduction studies were performed on 6 cases
and were abnormal in only one case, who had neuropathic and axonal changes. Visual evoked
response was abnormal in 5 of 10 cases.
Muscle biopsy was performed in 14 cases, and was abnormal in 10 (Table 1): three had
ragged red fibers (Figure 1) and four COX-negative fibers, excessive lipid accumulation was
observed in 7 cases and abnormal respiratory chain activities in 9 cases (supplementary file
2). Interestingly, most Alpers patients had normal respiratory chain enzyme activities or
isolated deficiency of a single enzyme complex, whilst those with MCHS had multiple
respiratory chain complex deficiencies (supplementary file 2).
Neuroimaging:
Magnetic resonance images (MRI) were available for 17 cases. The majority (n=14/17, 82%)
showed abnormality at disease onset. The most common MRI finding was cortical focal
lesions manifesting as T2/FLAIR hyperintensities involving cortical and subcortical areas,
predominantly affecting the occipital lobes (Fig 1). Less frequently, T2-hyperintense thalamic
lesions (n=3/17, 18%) and cerebellar atrophy (n=1/17, 6%) were observed (Table 1).
Genetic findings:
All cases had two confirmed pathogenic POLG variants identified either by targeted mutation
analysis for specific common mutations (c.1399G>C, p.Ala467Thr and c.2243G>C,
p.Trp748Ser) or by sequence analysis of all coding regions of POLG. Two novel POLG gene
mutations (c.1493A>C, p.Lys498Thr, and c.1862 G>A, p.Gly621Asp) were identified (cases
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23 and 26). The c.2492A>G, p.Tyr831Cys change has a relatively high population frequency
(0.006277; Exome Aggregation Consortium (ExAC), Cambridge, MA),30 but when it occurs
in trans with a severe mutation such as c.3401A>G, p.His1134Arg it is clearly pathogenic. All
POLG mutations and associated phenotypes identified in this study are illustrated in figure 2.
Phenotype spectrum:
Six patients fulfilled diagnostic criteria for MCHS, 19 for Alpers and one for a MNGIE-like
phenotype. One patient was unclassified owing to insufficient data. The median age at onset
for the MCHS group was 4.7 months (range 0.9-7 months) compared to 12.4 months (range
0.9-80.4 months) for the Alpers group. All patients with MCHS had liver pathology,
hypotonia and failure to thrive. None had seizures (Table 2). Five additional patients from the
literature review fulfilling diagnostic criteria for MCHS 19,22,31 had similar clinical features
and also did not have seizures (Table 2). The common founder mutations c.1399G>C,
p.Ala467Thr and c.2243G>C, p.Trp748Ser were present in one MCHS case in our cohort
(case 16) and one case in the literature. All cases in our cohort fulfilling diagnostic criteria for
Alpers syndrome had epilepsy (19/19). One patient was classified as having a MNGIE-like
phenotype (case 27). This is a 7 year old boy, who presented at the age of 3 months with
failure to thrive, progressive gastro-intestinal dysmotility, vomiting, and gradually became
dependent on total parental nutrition. He has muscle weakness, absent lower limb reflexes and
is wheelchair dependent. He is developmentally delayed and has learning difficulties. He has
no liver pathology, seizures or leukoencephalopathy.
Survival analysis:
Of 27 patients, 4 were alive at the time of data analysis, and one had been lost to follow up.
Median age at death was 15.8 months (range 1.0 to 184.6 months), whereas median time from
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disease onset to death was 4.9 months (range 0.5 to 181.2 months). The main causes of death
were liver failure (13/22), sepsis (5/22) and status epilepticus (4/22). Median survival time of
patients with disease onset ≤12 months was 3.6 months ( range 0.5-181) compared to 10 
months (range 1.4-82) for those with disease onset >12 months. Further analysis showed that
median survival time of patients with epilepsy was 4 months (range 0.5-181), compared to 5
months (range 0.5-91) for those without epilepsy. Survival analysis by phenotype showed that
the median survival time for patients with MCHS was 5 months (range 0.6-22) and 4 months
(range 0.5- 181) for Alpers.
DISCUSSION
Diagnosis of mitochondrial disorders is still a major challenge, particularly in the pediatric
population. POLG mutations are associated with a wide and overlapping spectrum of
phenotypes and while several major clinical entities are now recognized, it is likely that
neither the full spectrum nor the extent to which the phenotypes overlap is yet known.5,6
Reports in adults of minor phenotypes such as MELAS-like, MNGIE-like, optic atrophy,
diabetes, hearing loss,7,8,10,11 have added to the confusion. The cornerstone of clinical
diagnosis is a relevant phenotypic classification that physicians in everyday clinical practice
can use. We have therefore analysed the largest pediatric cohort to date to provide a
comprehensive clinical description of pediatric patients with POLG-related disease.
We found that the majority of patients had relatively diffuse clinical features with hypotonia,
developmental delay, failure to thrive and seizures. These non-specific clinical features
overlap with the manifestations of other mitochondrial disorders presenting during early
childhood including: Alpers syndrome caused by defects in other genes (e.g. TWNK, FARS2,
NARS2 and PARS2),32-36 and causes of Leigh syndrome such as SURF1 deficiency.37-39
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Consequently, identifying which individuals to screen for POLG mutations in the neonatal
period and early childhood is challenging. Further, our study showed that early onset POLG-
related disorders are associated with high mortality (n=22/26, 85%). The elapsed median time
from disease onset to death was 5 months, highlighting the rapid disease progression. As a
result, early clinical recognition and diagnosis is particularly urgent, especially in families
seeking prenatal diagnosis.
Epilepsy was one of the major clinical features, and was present in 89% (n=17/19) at disease
onset. Seizure semiology was similar to that reported in adult onset POLG-related disorders
17,39 with predominance of focal and focal evolving to bilateral convulsive seizures and
epileptiform discharges over occipital regions. Ataxia, movement disorders and stroke-like
episodes were less frequent compared to adults with POLG mutations. Cataract and
retinopathy have been reported in adults,10,18 but we now describe two pediatric patients with
cataract and two with optic atrophy. Diabetes and cardiomyopathy were not present in our
pediatric cohort. Despite the overlapping features between early and later onset POLG-related
disorders, it is clear from our study, and our literature review, that these two groups are not
identical and we feel they should be considered as two separate entities.
Regarding phenotypic classification, our data reinforced the current understanding of Alpers
and MCHS as two separate entities with different age of onset and survival. We found,
however, significant overlap in clinical features between the Alpers and MCHS subgroups
and application of the previously described criteria for diagnosis 12,23 was challenging. Using
the characteristic liver pathological findings to differentiate, as previously suggested,12 was
not possible as liver biopsy was only performed in three of our cases. This likely reflects
clinical practice where liver biopsy is rarely performed in the neonatal and pediatric setting,
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because of the attendant risks of morbidity and mortality. Moreover, not all patients with the
Alpers phenotype even show liver enzyme abnormalities. By comparing our cohort of patients
with Alpers and those with MCHS, we found, however, that epilepsy was exclusively
associated with the Alpers phenotype (Table 3). To confirm this, we conducted a systematic
literature review to identify previously published MCHS cases (Table 2), and found too that
none of these had epilepsy. Further, the most severe respiratory chain defects were observed
in the MCHS group, supporting the view that these patients are more severely affected and
potentially die before the onset of seizures. Discordance observed in one sibling pair (cases 15
and 16) provides further evidence for this hypothesis. Case 15 died at 9 months with
intractable seizures whereas his sister case 16 died at 5 months and never developed seizures.
Based on our findings, we suggest that instead of using complicated clinical and
histopathological criteria to differentiate between Alpers and MCHS phenotypes, the
classification of early onset POLG-related disorders can be simplified into those with or
without epilepsy.
Our cohort also includes a patient with an early onset MNGIE-like phenotype without
leukoencephalopathy (patient 27). This expands the phenotypic spectrum in this age group
and demonstrates the importance of considering POLG-related disorders in children with
severe gastrointestinal dysmotility even in the absence of liver pathology, seizures or
characteristic neuro-radiological findings for POLG disease.
Previous reports have recommended screening for the common founder POLG mutations in
children younger than 12 years with unexplained encephalopathy, or multi-system
neurological disorders.11,40 Since these mutations (c.1399G>A, p.Ala467Thr and c.2243G>C,
p.Trp748Ser) were identified only once in in our MCHS cohort (patient 16) and one
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previously published MCHS case,31 there is a high risk of missing the diagnosis in these
patients, demonstrating clearly the limited value of screening only for common POLG
mutations in this age group.
In conclusion, while early onset POLG-related disease is associated with complex
overlapping phenotypes, we suggest classification can be simplified according to the presence
or absence of epilepsy. We provide a detailed description of the natural history of early onset
POLG-related disorders, and a simplified classification to facilitate clinical recognition of
these disorders by neonatologists and pediatricians. Furthermore, we demonstrate the need to
perform full sequence analysis of the entire POLG gene rather than targeting common POLG
mutations in patients with unexplained encephalopathy and multi-system disorders with or
without epilepsy, both in the neonatal period and during childhood.
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Figure legends:
Figure 1. Upper panel: EEG traces and MRI scans recorded during the same period of
hospitalization in two patients with Alpers syndrome caused by POLG mutations.
A (case 2): EEG tracing displayed at 30mm/cm, 150 µV/cm, 0.01-30Hz. EEG shows high
voltage polyspike-slow and sharp-slow wave around 1-2Hz frequency in the right
occipitotemporal channels. Axial T2-weighted MRI shows bilateral high T2 signal consistent
with cortical edema, in the occipitotemporal regions.
B (case 4): EEG tracing displayed at 30mm/cm, 500µV/cm, and 0.01-30Hz. Periodic
polyspike-slow waves localized at the left occipitotemporal area. Axial T2-weighted MRI
shows bilateral cortical edema, in the occipitotemporal regions.
Lower panel: Muscle histochemistry from three cases shows occasional fibres with dense
mitochondrial accumulations on the Gömöri trichrome stain (a case 17, b case 18, and c case
4). In a few fibres, these formed subsarcolemmal accumulations that indented the sarcoplasm
on at least two sides as seen typically in ragged red fibres (a, b).
Figure 2. Schematic diagram of the POLG gene illustrating mutations identified in this study.
Mutations associated with the Alpers and MCHS phenotypes are located throughout the gene,
i.e. in the exonuclease, linker and polymerase domains. The mutations in the patient with a
MNGIE-like phenotype were also present in patients with Alpers and MCHS.
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Table 1. Major clinical, laboratory, electroencephalography (EEG), and neuroimaging
findings.
Table 2. Summary of the clinical and genetic findings for patients with MCHS included in
this study and those reported in the literature.
Table 3. Comparison between patients with MCHS and Alpers phenotypes included in the
study cohort

Figure 2. Schematic diagram of the POLG gene illustrating mutations identified
in this study. Mutations associated with the Alpers and MCHS phenotypes are
located throughout the gene, i.e. in the exonuclease, linker and polymerase
domains. The mutations in the patient with a MNGIE-like phenotype were also
present in patients with Alpers and MCHS. The E1143G and Q1236H that not
considered definitely pathological are associated with other known pathogenic
mutations. The novel mutations identified in this study are in red.
Table 1. Major clinical, laboratory, electroencephalography (EEG), and neuroimaging
findings
A. Clinical features Number of patients
at onset
Number of patients during disease
course
1- Neurological (n=27 /27)
Seizures 17/19 19/26(73%)
 Primary generalized tonic -clonic none
 Myoclonic 13/19 (68%)
 Status epilepticus 13/19 (68%)
 Epilepsia partialis continua 11/19 (58%)
 Focal evolving to bilateral convulsive 14/19 (74%)
 Focal 14/19 (74%)
 Infantile spasm 1/19 (5%)
 Therapy resistant epilepsy 17/19 (89%)
Stroke-like episodes 2/5 5/18 (28%)
Hypotonia 22/22 22/23(96%)
Ataxia 0/12 2/14 (14%)
Dystonia 2/3 3/24 (12 %)
Hearing impairment 2/2 2/20 (10%)
2- Ophthalmological (n=12/23)
Ptosis none none
Progressive external ophthalmoplegia none none
Cataract 2/2 2/23 (9%)
Optic atrophy 2/2 2/23 (9%)
Visual impairment not classified 2/4 4/23(17%)
Nystagmus 2/6 6/23 (26%)
3-Gastro-intestinal (n=25/27)
Faltering growth 22/24 24/27 (89 %)
Vomiting 18/22 22/26 (85%)
Liver dysfunction 14/23 23/25 (92 %)
Chronic diarrhea 1/1 1/17 (6 %)
4-Endocrine (n= 4/27)
Diabetes mellitus none none
Hypoglycemia 2/3 3/27 (11 %)
Hypoparathyroidism 1/1 1/27 (4%)
Hypothyroidism 1/1 1/27 (4%)
Growth hormone deficiency none none
5-Renal (n:=3/7)
Renal tubular dysfunction 2/3 3/27 (11 %)
B. Laboratory findings Number of patients with pathological values at onset
1- Blood:
Elevate lactate 12/20
Elevated creatine kinase 1/5
Low albumin 14/20
Elevated aspartate aminotransferase 13/20
Elevated alanine aminotransferase 7/14
Elevated gamma glutamyl transferase 9/10
2- Cerebrospinal fluid
Elevated lactate 2/5
Elevated protein 11/14
3- Muscle biopsy:
Pathological finding 10/14
Red –ragged fibers 3/14
COX –negative fibers 4/14
Excessive fluid accumulation 7/14
Abnormal respiratory chain activities 9/14
C. EEG findings – epileptiform activities
in:
Frontal lobe 4/19 (21 %)
Parietal lobe 4/19 (21 %)
Temporal lobe 2/19 (10 %)
Occipital lobe 10/19 (53 %)
Multifocal 7/19 (37 %)
D. Magnetic resonance imaging (MRI) findings
MRI lesions at onset 14/17 (82%)
MRI lesions during disease course 15/17 (88%)
General cerebral atrophy 4/17 (23%)
CFL frontal lobe 4/17 (23%)
CFL parietal /temporal lobe 3/17 (18%)
CFL occipital lobe 6/17 (35%)
White matter lesions 5/17 (29%)
Thalamus 3/17 (18%)
Cerebellum atrophy 1/17 (6%)
CFL: cortical focal lesions
Table 2. Summary of the clinical and genetic findings for patients with MCHS included in this study and those reported in the literature
Case study
number
Age of
onset
Hypotonia Developmental
delay
Epilepsy Faltering
growth
Liver
dysfunction
Hypo-
glycemia
Renal
dysfunction
Ophthalmological
disorder
Cause of
death
Mutations
8 5 m + + - + + - -
Optic atrophy,
nystagmus
Liver
failure
His1110Tyr+Gln1236His/
Trp748Ser+Glu1143Gly
9 7 m + + - + + + -
Liver
failure
Arg232His/Gly848Ser
10 6 m + + - + + - -
Liver
failure
Arg232His/Gly848Ser
11 3 m + + - + + + + Cataract
Liver
failure
Thr251IIe+Pro587Leu/
Glu1136Lys
12 4 m + + - + + + + Cataract
Liver
failure
Thr251IIe+Pro587Leu/
Glu1136Lys
15 1 m + + - + + - +
Visual
impairment
Liver
failure
Tyr831Cys/ His1134Arg
Previously reported
(Reference)
A(22) 3 m + + - + + + - -
Liver
failure
Thr251IIe/ Pro587Leu
B (19) 7 m + + - + + NA + -
Liver
failure
Arg232His/Asp1184Asn
C (19) 4 m + + - + + NA + -
Liver
failure
Arg232His/Asp1184Asn
D(30) 24 m + + - + + NA - Ptosis
Liver
failure
Gly848Ser/ Arg1096Cys
E(30) 7 m + + - + + NA + NA
Liver
failure
Ala467Thr/ Ser1095Arg
m: months, NA: not available, +: present, - : absent.
Table 3. Comparison between patients with MCHS and Alpers phenotypes included in the study
cohort
Clinical and laboratory findings MCHS Alpers
Perinatal abnormality 3/6 (50%) 8/19 (42%)
Hypotonia 6/6 (100%) 15/17 (88%)
Developmental delay 6/6 (100%) 16/19 (84%)
Seizures 0/6 (0%) 19/19 (100%)
Liver dysfunction 6/6 (100%) 19/19 (100%)
Renal tubular dysfunction 3/6 (50%) 0/19 (0%)
Ophthalmological disorders 4/6 (67%) 7/16 (37%)
Respiratory chain enzyme deficiency 5/5 (100%) 6/9 (67%)
Case study Number Diagostic center Ethnicity Age of onset ( months) Age at death( months) Phenotype Mutations (polymorphism)
1 Norway Northern European 11.23 12.9 Alpers p.Ala467Thr/p.Gly303Arg
2 Norway Northern European 23.5 105.43 Alpers p.Ala467Thr/p.Gly303Arg
3 Norway Northern European 5.83 8.17 Alpers p.Ala467Thr/p.Gly848Ser
4 Norway Northern European 15.17 20.03 Alpers p.Ala467Thr/p.Gly303Arg
5 Norway Northern European 12.07 18.87 Alpers p.Trp748Ser/ p.Gly1052Asp
6 Norway Northern European 15.17 18.8 Alpers p.Trp748Ser/ p.Arg807Cys
7 Norway Northern European 12.53 15.8 Alpers p.Trp748Ser/p.Arg807Cys
8 Norway Northern European 11.87 15.87 Alpers p.Gly303Arg/p.Ala467Thr
9 UK Northern European 1.47 13.87 Alpers p.Ala467Thr/p.Thr914Pro
10 UK Northern European 16.87 Alive Alpers p.Ala467Thr/ C.3483-4_3497 del
11 UK Northern European 11.47 13.9 Alpers p.Ala467Thr/p.Gly848Ser
12 UK Middle East/UAE 13.83 Alive Alpers p.Arg1096Cys/p.Arg1096Cys
13 UK Northern European 8.53 11.77 Alpers p.Arg807His/p.Gly1052Ser
14 UK Northern European 80.43 NA Alpers p.Ala467Thr/p.Ala467Thr
15 UK Northern European 2.03 8.97 Alpers p.His1110Tyr+ (p.Gln1236His) /
p.Trp748Ser+(p.Glu1143Gly)
16 UK Northern European 4.77 5.33 MCHS p.His1110Tyr+(p.Gln1236His)/
p.Trp748Ser+(p.Glu1143Gly)
17 UK Northern European 7 30.07 MCHS p.Arg232His/p.Gly848Ser
18 UK Northern European 6.33 25.37 MCHS p.Arg232His/p.Gly848Ser
19 UK Cyprus 3.33 5.37 MCHS p.Thr251IIe+p.Pro587Leu/p.Glu1136Lys
20 UK Cyprus 4.6 9.57 MCHS p.Thr251IIe+p.Pro587Leu/p.Glu1136Lys
21 UK Pakistan 0.93 1.47 Alpers p.Arg227Trp/p.Arg227Trp
22 UK Northern European 0.93 6.03 MCHS p.Tyr831Cys)/p.His1134Arg
23 UK Northern European 3.47 Alive Alpers p.Gly848Ser/p.Lys498Thr (novel)
24 UK Northern European 0.57 1.03 Unclassified p.Tyr831Cys/p.His 1134Arg
25 UK Northern European 36.7 68.47 Alpers p.Ala476Thr/p.Ala467Thr
26 UK Northern European 18.27 32.03 Alpers p.Ala467Thr/p. Gly621Asp (novel)
27 UK Northern European 2.83 Alive MNGIE p.Arg232His/p.Gly848Ser
NA: not avilable , UAE: United Arab Emirates, MCHS: myocerebrohepatopathy spectrum, MNGIE: mitochondrial neurogastrointestinal encephalopathy
Supplementary file 1. Summary of the study cohort
Supplementary file 2 : POLG Respiratory chain enzyme activities
Case
nr.
Phenotype Complex I Complex II Complex I:II
Ratio
Complex III Complex II+III Complex IV Comment Reference
range
1 Alpers 0.024 0.034 0.192 0.144 Multiple enzyme
deficiencies
a
3 Alpers 0.093 0.249 0.373 1.212 Isolated complex I
deficiency (low I:II)
a
8 Alpers † Isolated complex I
deficiency
a
11 Alpers 0.151 0.084 0.018 Normal b
12
Alpers
0.156 0.079 0.004 Isolated complex IV
deficiency
b
13 Alpers 0.126 0.159 0.026 Normal b
13*
Alpers
0.081 0.031 0.007 Multiple enzyme
deficiencies
c
14 Alpers 0.126 0.159 0.026 Normal b
15 Alpers 0.146 0.133 0.020 Normal b
17
MCHS
0.097 <0.001 0.006 Multiple enzyme
deficiencies
b
18
MCHS
0.061 0.019 0.008 Multiple enzyme
deficiencies
b
19
MCHS
0.058 0.014 0.004 Multiple enzyme
deficiencies
b
20
MCHS
0.091 0.084 0.011 Multiple enzyme
deficiencies
b
21 Alpers 0.157 0.070 0.023 Normal b
a Reference range
(Norway cases
muscle)
0.104 ± 0.036 0.145± 0.047 0.52-0.95 0.554±0.345 1.124±0.511 a
b Reference range
(UK cases muscle)
0.104-0.268 0.040-0.204 0.014-0.034 b
c Reference range
(UK cases liver)
0.054-0.221 0.057-0.204 0.011-0.031 c
† Reported as abnormal, no figures available; *liver biopsy
